Regeneron Halted Ahead Of FDA

Shares of Regeneron Pharmaceuticals Inc. REGN are halted going into a meeting with the U.S. Food and Drug Administration and the Dermatologic and Ophthalmic Drugs Advisory Committee to discuss Regeneron's license application for treating certain kinds of vision loss. The drug, EYLEA or VEGF Trap-Eye, controls the over-development of new blood vessels in eyes that can happen in older people and lead to swelling near the persons retina. The target data for the FDA decision on Eylea is August 20. Shares of Regeneron closed at $56.72 yesterday.